Celine Ord, MD
Radiation Oncology · Fredericksburg, TXNPI 1457526048
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $716, more than ten times the $17 reported in 2019.
Across 44 payments — averaging $23.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$125
- AstraZeneca$103
- Regeneron Healthcare Solutions, Inc.$94
- Johnson & Johnson$72
- Bristol Myers Squibb$72
- Siemens Medical Solutions USA, Inc.$66
- plus $520 from 16 others
What the payments were for
- Food & beverage$1,053100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 5 | $125 |
| AstraZeneca | 4 | $103 |
| Regeneron Healthcare Solutions, Inc. | 4 | $94 |
| Johnson & Johnson | 3 | $72 |
| Bristol Myers Squibb | 3 | $72 |
| Siemens Medical Solutions USA, Inc. | 3 | $66 |
| Blue Earth Diagnostics | 3 | $64 |
| Sanofi | 2 | $63 |
| AbbVie | 2 | $57 |
| Incyte Corporation | 2 | $46 |
| Novartis | 2 | $34 |
| Sobi, Inc | 1 | $33 |
| Deciphera Pharmaceuticals Inc. | 1 | $29 |
| Tersera Therapeutics LLC | 1 | $28 |
| Eisai Inc. | 1 | $28 |
| Coherus Oncology, Inc. | 1 | $27 |
| Pharmacosmos Therapeutics Inc. | 1 | $24 |
| Bayer | 1 | $23 |
| Boston Scientific | 1 | $20 |
| Blueprint Medicines Corporation | 1 | $19 |
| Octapharma USA, Inc. | 1 | $14 |
| Foundation Medicine, Inc. | 1 | $12 |
How this compares
$1,053 in reported general payments places this provider in the 60th percentile of 418 radiation oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 23 | $469 |
| Lidocaine Hcl ViscousLidocaine Hcl | 11 | $301 |
| Tamsulosin Hcl | 36 | $271 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Fredericksburg
- James WelshHouston$421K
- Stephen ChunHouston$344K
- Jim HsiangCorpus Christi$258K
- Chad TangHouston$183K
- Phuoc TranHouston$177K
- Hak ChoyDallas$119K
- Steven LinHouston$105K
- Benjamin SchrankHouston$100K
- Robert TimmermanDallas$77K
- Abhilasha PatelHouston$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.